Other languages Arvinas, Inc.

Equities

ARVN

US04335A1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
32.54 ^USD	-4.15%		-2.72%	-20.94%

Apr. 15	H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating	MT
Apr. 12	HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	Apr. 12
Novartis : accord de licence dans le cancer de la prostate	Apr. 11
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	Apr. 11
Novartis étend sa recherche contre le cancer de la prostate	Apr. 11
Novartis erweitert Pipeline mit Lizenzabkommen für Prostatakrebs-Kandidaten	Apr. 11
Novartis licenses Arvinas' cancer drug for up to $1 billion	Apr. 11
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer	Apr. 11
Arvinas Appoints Noah Berkowitz as Chief Medical Officer	Mar. 18
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee	Mar. 18
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue	Feb. 27
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Arvinas, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Arvinas, Inc. Announces Executive Changes, Effective February 29, 2024	Feb. 20
Early-Stage Trial of Arvinas, Pfizer's Vepdegestrant Combined With Samuraciclib to Potentially Treat Metastatic Breast Cancer Gets Underway	Feb. 14
Arvinas, Pfizer's Breast Cancer Treatment Vepdegestrant Receives FDA Fast-Track Investigation Designation	Feb. 06
Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy	Feb. 06
Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel	Jan. 16
A Wall Street, record pour le Dow Jones, le S&P 500 tout près de son sommet	Dec. 19
Arvinas Shares Climb After Wells Fargo Upgrade	Dec. 19
En modeste hausse, Wall Street tente de réaliser une autre semaine positive	Dec. 19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Arvinas, Inc.

Equities

ARVN

US04335A1051

Other languages

Filters